Literature DB >> 10443690

Expression of calcium-sensing receptor and characterization of intracellular signaling in human pituitary adenomas.

R Romoli1, A Lania, G Mantovani, S Corbetta, L Persani, A Spada.   

Abstract

Extracellular Ca(2+)-sensing receptor (CaSR) has been recently identified in rat and mouse pituitary and in AtT-20 cells. The aim of the study was to investigate the presence of CaSR in the human pituitary and its signaling pathway. Normal parathyroid biopsies, autoptic normal pituitaries, and seven nonfunctioning and six GH-secreting adenomas were studied. Southern blot analysis of the RT-PCR products from pituitary adenomas indicated that the PCR fragments obtained were products of specific amplification of CaSR messenger ribonucleic acid. Sequence analysis showed nucleotide identity of these products with the available human parathyroid CaSR. By immunoblotting analysis CaSR, was detected in normal and adenomatous pituitary tissues. In all tumors studied, extracellular Ca2+ (2.5 mmol/L) induced a significant increase in intracellular Ca2+, mainly due to Ca2+ mobilization (from 82.7+/-11 to 148+/-36 nmol/L; P < 0.001). Similar results were obtained with the CaSR activators gadolinium and neomycin. Moreover, CaSR activators significantly increased cAMP levels; this effect was not mimicked by other agents able to increase intracellular Ca2+, such as TRH. CaSR agonists did not increase resting GH secretion in any GH-secreting adenomas, but amplified the GH response to GHRH. In this study we first demonstrate CaSR expression in the human pituitary and provides evidence for an additional mechanism by which calcium might regulate pituitary cell function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10443690     DOI: 10.1210/jcem.84.8.5922

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  The calcium-sensing receptor couples to Galpha(s) and regulates PTHrP and ACTH secretion in pituitary cells.

Authors:  Ramanaiah Mamillapalli; John Wysolmerski
Journal:  J Endocrinol       Date:  2009-12-23       Impact factor: 4.286

Review 2.  Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.

Authors:  Siqi Wen; Chunling Li; Xianquan Zhan
Journal:  EPMA J       Date:  2022-02-17       Impact factor: 6.543

3.  The bromodomain inhibitor JQ1+ reduces calcium-sensing receptor activity in pituitary cell lines.

Authors:  Kate E Lines; Anna K Gluck; Supat Thongjuea; Chas Bountra; Rajesh V Thakker; Caroline M Gorvin
Journal:  J Mol Endocrinol       Date:  2021-07-26       Impact factor: 5.098

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.